Utilization of authorization within Vitrolife to repurchase own shares

Utilization of authorization within Vitrolife to repurchase own shares

The Annual General Meeting on April 29, 2008, of Vitrolife AB (publ) approved
the proposal to authorize the Board of Directors to acquire the company's own
shares for the purpose of adjusting the company's capital structure and/or use
repurchased shares in connection with the acquisition of a company or business.
The company's Board has now decided to utilize this authorization. 

The shares will be purchased over the OMX Nordic Exchange Stockholm at a price
within the quoted price range at any given time when the Board finds it
favourable for the company's shareholders. 

Purchase can be made as of August 2, 2008, until the next Annual General Meeting
in 2009. No acquisitions will be made during a 30-day period prior to the
announcement of quarterly results, the day of announcement included. 

The total number of outstanding shares in Vitrolife is 19,800,157 and the
maximum number of shares which can be repurchased is 1,980,015. 



August 1, 2008
Kungsbacka, Sweden 

Vitrolife AB (publ)







Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act. The information was submitted for publication on August 1, 2008
at 10.30 am.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.